Tykerb Discovery: A Dual EGFR and ERBB2 Tyrosine Kinase Inhibitor

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 41-56

  Lackey, Karen ^a   Cockerill, G Stuart ^b  

^a GLAXOSMITHKLINE   (United States)

^b Arrow Therapeutics   (United Kingdom)

Author keywords

Drug candidate selection; Inhibiting erbB2 and EGFR tyrosine kinase activity; Tykerb discovery dual EGFR and erbB2 tyrosine kinase inhibitor

Indexed keywords

EID: 84889805263     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch2     Document Type: Chapter

References (36)

1. Alroy, I., and Yarden, Y. (1997). The erbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions . FEBS Lett. 410, 83-86.
2. Baselga, J., and Averbuch, S. G. (2000). ZD1839 (" Iressa ") as an anticancer agent. Drugs. 60 (Suppl. 1), 33-40.
3. Bence, A. K., Anderson, E. B., Halepota, M. A., et al. (2005). Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR -ErbB-2 inhibitor, in healthy subjects. Invest New Drugs. 23 (1), 39-49.
4. Brandt, B., Vogt, U., Sclotter, C. M., et al. (1995). Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene. 159, 35-42.
5. Brignola, P. S., Lackey, K., Kadwell, S. H., et al. (2002). Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains:demonstration of differential sensitivity to kinase inhibitors. J Biol Chem. 277 (2), 1576-1585.
6. Cockerill, G. S., Stubberfield, C., Stables, J., et al. (2001). Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2. Bioorg Med Chem Lett. 11 (11), 1401-1405.
7. de Bono, J. S., and Rowinsky, E. K. (2002). The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 8 (4), S19-S26.
8. Downward, J., Yarden, Y., Mayes, E., et al. (1984). Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences. Nature. 307, 521-527.
9. Fabian, M. A., Biggs, W. H., Treiber, D. K., et al. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 23 (3), 329-336.
10. Fry, D. W., Kraker, A. J., McMichael, A., et al. (1994). A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265 (5175), 1093-1095.
11. Harris, R. A., Eichholtz, T. J., Hiles, I. D., et al. (1999). New model of erbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer. 80 (3), 477-484.
12. Hopkins, A. L., Groom, C. R., and Alex, A. (2004). Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 9 (10), 430-431.
13. Karaman, M. W., Herrgard, S., Treiber, D. K., et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26 (1), 127-132.
14. Keith, B. R., Allen, P. P., Alligood, K. J., et al. (2001). Anti-tumor activity of GW2016 in the erbB-2 positive human breast cancer xenograft, BT474. Proceedings of the American Association of Cancer Research 92nd Annual Meeting.
15. Klapper, L. N., Kirschbaum, M. H., Sela, M., and Yarden, Y. (2000). Biochemical and clinical implications of the erbB/HER signaling network of growth factor receptors. Adv Cancer Res. 77 : 25-79.
16. Lackey, K. E. (2006). Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Topics Med Chem. 6 (5), 435-460.
17. Lichtner, R. B., Menrad, A., Sommer, A., et al. (2001). Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 61, 5790-5795.
18. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 23 (1-3), 3-25.
19. Modjtahedi, H., Affleck, K., Stubberfield, C., and Dean, C. (1998). EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol. 13, 335-342.
20. Moghal, N., and Sternberg, P. W. (1999). Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol. 11 (2), 190-196.
21. Mullin, R. J. (2003). Discovery and profile of GW572016, a dual reversible EGFR/ErbB-2 tyrosine kinase inhibitor. Abstracts of Papers, 226th ACS National Meeting, New York.
22. Pasleau, F., Grooteclaes, M., and Gol-Winkler, R. (1993). Expression of the c-erbB-2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB-2 mRNA half-life. Oncogene. 8, 849-854.
23. Pearson, M. A., and Fabbro, D. (2004). Targeting protein kinases in cancer therapy: a success? Exp Rev Anticancer Ther. 4 (6), 1113-1124.
24. Ranson, M. (2004). Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 90 (12), 2250-2255.
25. Riese, D. J., and Stern, D. F. (1998). Specificity within the EGF family/ErbB receptor family signaling network. BioEssays. 20 (1), 41-48.
26. Rusnak, D. W., Affleck, K., Cockerill, S. G., et al. (2001a). The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 61 (19), 7196-7203.
27. Rusnak, D. W., Lackey, K., Affleck, K., et al. (2001b). The effects of the novel, reversible EGFR/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 1 (2), 85-94.
28. Sainsbury, J. R., Farndon, J. R., Needham, G. K., et al. (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1398-1402.
29. Semba, K., Kamata, N., Toyoshima, K., and Yamamoto, T. (1985). A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA. 82, 6497-6501.
30. Shaffer, J. E., Adkison, K. K., Halm, K., et al. (1999). Use of " N-in-one " dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. J Pharm Sci. 88 (3), 313-318.
31. Spector, N. L., Xia, W., Burris, H., et al. (2005). Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB-2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 23 (11), 2502-2512.
32. Stamos, J., Sliwkowski, M. X., and Eigenbrot, C. (2002). Structure of the EGF receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 277, 46265-46272.
33. Tiseo, M., Loprevite, M., and Ardizzoni, A. (2004). Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents. 4 (2), 139-148.
34. Wood, E. R., Truesdale, A. T., McDonald, O. B., et al. (2004). Unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationship between protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (18), 6652-6659.
35. Xia, W., Mullin, R. J., Keith, B. R., et al. (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB-2 and downstream Erk1/2 and AKT pathways. Oncogene. 21 (41), 6255-6263.
36. Yarden, Y., and Sliwkowski, M. X. (2001). Untangling the erbB signaling network. Nature Rev. 2, 127-137.